Contrasting of Aldeyra Therapeutics Inc. (ALDX) and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX)

We are comparing Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aldeyra Therapeutics Inc. N/A 0.00 38.89M -1.77 0.00
Syndax Pharmaceuticals Inc. 1.52M 77.29 73.96M -3.01 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Aldeyra Therapeutics Inc. 0.00% -99.8% -85.2%
Syndax Pharmaceuticals Inc. -4,865.79% -91.1% -64.7%


The current Quick Ratio of Aldeyra Therapeutics Inc. is 4.8 while its Current Ratio is 4.8. Meanwhile, Syndax Pharmaceuticals Inc. has a Current Ratio of 5.6 while its Quick Ratio is 5.6. Syndax Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Aldeyra Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for Aldeyra Therapeutics Inc. and Syndax Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aldeyra Therapeutics Inc. 0 0 3 3.00
Syndax Pharmaceuticals Inc. 0 0 0 0.00

$29.67 is Aldeyra Therapeutics Inc.?s consensus price target while its potential upside is 298.26%.

Insider and Institutional Ownership

Aldeyra Therapeutics Inc. and Syndax Pharmaceuticals Inc. has shares owned by institutional investors as follows: 76.1% and 72.9%. Insiders owned 0.94% of Aldeyra Therapeutics Inc. shares. On the other hand, insiders owned about 0.1% of Syndax Pharmaceuticals Inc.?s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aldeyra Therapeutics Inc. 4.71% -9.19% -11.11% 3.23% -4.19% -3.61%
Syndax Pharmaceuticals Inc. 9.24% 22.5% 35.04% -11.37% -27.02% 54.16%

For the past year Aldeyra Therapeutics Inc. had bearish trend while Syndax Pharmaceuticals Inc. had bullish trend.


Syndax Pharmaceuticals Inc. beats Aldeyra Therapeutics Inc. on 6 of the 10 factors.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.